Respiratory Support With Nasal High Flow Reduces Opioid Requirements During Endoscopic Retrograde Cholangiopancreatography

ABSTRACT Objectives Nasal high flow (NHF) improves oxygenation, reduces the work of breathing, and stabilizes ventilation. In endoscopic retrograde cholangiopancreatography (ERCP) under dexmedetomidine‐based sedation, opioids are often required but increase the risk of respiratory depression and delayed recovery. This study tested the hypothesis that NHF therapy, compared with low‐flow oxygen (LFO), may reduce opioid requirements during ERCP. Methods This open‐label, single‐center, randomized controlled trial enrolled patients undergoing ERCP under dexmedetomidine‐based sedation. Patients were randomized to NHF or LFO. Sedation used dexmedetomidine, midazolam and pethidine with a standardized protocol. The primary endpoint was total pethidine dose. Secondary endpoints included transcutaneous carbon dioxide (TcCO 2 ), oxygenation‐perfusion parameters, processed electroencephalography (EEG) parameters, sedative doses, and sedation depth. Results Enrollment ended early at a total of 94 of the planned 118 patients due to slow recruitment (NHF 47, LFO 47). Poisson regression demonstrated reduced opioid requirements with NHF (incidence rate ratio 0.77, 95% confidence interval, 0.62–0.96, p = 0.023). The total pethidine dose was lower in the NHF group (medians 43.75 mg vs. 70.00 mg, p = 0.004). The TcCO 2 and oxygenation‐perfusion parameters were comparable between groups. EEG tests showed lower patient state index and electromyographic activity in the NHF group, indicating deeper sedation. No adverse events attributable to interventions were observed. Conclusion NHF reduced opioid requirements while maintaining oxygenation, ventilation, and sedation during ERCP. The ability of NHF to provide respiratory support, ensure adequate oxygenation, and allow monitoring of breathing makes it a promising modality during procedural sedation; however, further multi‐center studies are needed. Trial Registration 072210047 [jRCTs]

Authors

Institutions

Publication Details

Journal
DEN Open
Published
2026-09-04
DOI
https://doi.org/10.1002/deo2.70421
Primary Topic
Anesthesia and Sedative Agents
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Respiratory Support With Nasal High Flow Reduces Opioid Requirements During Endoscopic Retrograde Cholangiopancreatography

Yasuhiko Nakao, Masafumi Haraguchi, Rintaro Yano, Hisamitsu Miyaaki et al.
DEN Open
Anesthesia and Sedative Agents
article

Respiratory Support With Nasal High Flow Reduces Opioid Requirements During Endoscopic Retrograde Cholangiopancreatography

Yasuhiko Nakao, Masafumi Haraguchi, Rintaro Yano, Hisamitsu Miyaaki, Akane Shimakura, Masanori Fukushima, Ryu Sasaki, Eisuke Ozawa, Stanislav Tatkov, Takao Ayuse, Tomotaka Mori, Taiga Ichinomia, Shuntaro Sato, Kosuke Takahashi, Satoshi Miuma, Tetsuya Hara
article en

Abstract

ABSTRACT Objectives Nasal high flow (NHF) improves oxygenation, reduces the work of breathing, and stabilizes ventilation. In endoscopic retrograde cholangiopancreatography (ERCP) under dexmedetomidine‐based sedation, opioids are often required but increase the risk of respiratory depression and delayed recovery. This study tested the hypothesis that NHF therapy, compared with low‐flow oxygen (LFO), may reduce opioid requirements during ERCP. Methods This open‐label, single‐center, randomized controlled trial enrolled patients undergoing ERCP under dexmedetomidine‐based sedation. Patients were randomized to NHF or LFO. Sedation used dexmedetomidine, midazolam and pethidine with a standardized protocol. The primary endpoint was total pethidine dose. Secondary endpoints included transcutaneous carbon dioxide (TcCO 2 ), oxygenation‐perfusion parameters, processed electroencephalography (EEG) parameters, sedative doses, and sedation depth. Results Enrollment ended early at a total of 94 of the planned 118 patients due to slow recruitment (NHF 47, LFO 47). Poisson regression demonstrated reduced opioid requirements with NHF (incidence rate ratio 0.77, 95% confidence interval, 0.62–0.96, p = 0.023). The total pethidine dose was lower in the NHF group (medians 43.75 mg vs. 70.00 mg, p = 0.004). The TcCO 2 and oxygenation‐perfusion parameters were comparable between groups. EEG tests showed lower patient state index and electromyographic activity in the NHF group, indicating deeper sedation. No adverse events attributable to interventions were observed. Conclusion NHF reduced opioid requirements while maintaining oxygenation, ventilation, and sedation during ERCP. The ability of NHF to provide respiratory support, ensure adequate oxygenation, and allow monitoring of breathing makes it a promising modality during procedural sedation; however, further multi‐center studies are needed. Trial Registration 072210047 [jRCTs]

DEN OpenVol. 7(1)
Japanese Red Cross Society, Japan (JP), Fisher & Paykel Healthcare (New Zealand) (NZ), Nagasaki University Hospital (JP), Nagasaki University (JP)
Fisher and Paykel Healthcare
Openalex Percentile: Top 8%
Anesthesia and Sedative Agents
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.